Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkx467PMID 29244108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose rifampicin, moxifl oxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

  2019cited by this paper
• High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

  2017cited by this paper
• Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model

  2016cited by this paper
• High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo

  2015cited by this paper
• A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

  2015cited by this paper
• Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients

  2015cited by this paper
• High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

  2014cited by this paper
• Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

  2014cited by this paper
• Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.

  2013cited by this paper
• Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

  2012cited by this paper
• Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

  2011cited by this paper
• Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum.

  2010cited by this paper
• The near future: improving the activity of rifamycins and pyrazinamide.

  2010cited by this paper
• WHO global tuberculosis control report 2010. Summary.

  2010cited by this paper
• Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears

  2007cited by this paper
• Antituberculosis drugs and hepatotoxicity.

  2007cited by this paper
• Shortening the treatment of tuberculosis

  2005cited by this paper
• Population Pharmacokinetics II: Estimation Methods

  2004cited by this paper
• Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin

  2004cited by this paper
• Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis

  2003cited by this paper
• Role of individual drugs in the chemotherapy of tuberculosis.

  2000cited by this paper
• Detection of mRNA Transcripts and Active Transcription in Persistent Mycobacterium tuberculosisInduced by Exposure to Rifampin or Pyrazinamide

  2000cited by this paper
• The action of antituberculosis drugs in short-course chemotherapy.

  1985cited by this paper
• Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations.

  1984cited by this paper
• The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.

  1977cited by this paper
• Two three-month treatment regimens for pulmonary tuberculosis.

  1976cited by this paper
• Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.

  1972cited by this paper
• THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUE

  1956cited by this paper
• FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUE

  1956cited by this paper

• Potential Alteration of Rifampicin's Bioavailability by Phyllanthus niruri Supplementation in Tuberculosis Therapy.

  2025cites this paper
• Efficacy of rifampicin combination therapy against MRSA prosthetic vascular graft infections in a rat model

  2024cites this paper
• High-Dose Rifampicin for 3 Months after Culture Conversion for Drug-Susceptible Pulmonary Tuberculosis

  2024cites this paper
• Spectroscopy and dynamics of beta-lactoglobulin complexed with rifampicin

  2023cites this paper
• Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.

  2023cites this paper
• Spectroscopic analysis to identify the binding site for Rifampicin on Bovine Serum Albumin.

  2022cites this paper
• Culture-Free Enumeration of Mycobacterium tuberculosis in Mouse Tissues Using the Molecular Bacterial Load Assay for Preclinical Drug Development

  2022cites this paper
• Therapeutic effect of an anti-tuberculosis agent, isoniazid, and its nano-isoform in ulcerative colitis.

  2021cites this paper
• Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin

  2021cites this paper
• The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies

  2020cites this paper
• Drug-Resistant Tuberculosis 2020: Where We Stand

  2020influential citation
• Treatment guidelines for tuberculosis and tuberculous meningitis

  2020cites this paper
• Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates.

  2020cites this paper
• MazEF-rifampicin interaction suggests a mechanism for rifampicin induced inhibition of persisters

  2020cites this paper
• Determination of organ specific pharmacokinetic data for the anti-tuberculosis drugs in guinea pigs using microdialysis

  2019cites this paper
• Regrowth of Mycobacterium tuberculosis Populations Exposed to Antibiotic Combinations Is Due to the Presence of Isoniazid and Not Bacterial Growth Rate

  2019cites this paper
• Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure.

  2019cites this paper
• Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model

  2018cites this paper
• Population/ Nonlinear mixed-effects modelling of pharmacokinetics and pharmacodynamics of tuberculosis treatment

  2018cites this paper
• The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

  2018cites this paper